King's Research Portal

DOI:

[10.1016/j.rpsm.2014.05.004](https://doi.org/10.1016/j.rpsm.2014.05.004)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Pina-Camacho, L., Diaz-Caneja, C. M., Saiz, P. A., Bobes, J., Corripio, I., Grasa, E., Rodriguez-Jimenez, R., Fernandez, M., Sanjuan, J., Garcia-Lopez, A., Tapia-Casellas, C., Alvarez-Blazquez, M., Fraguas, D., Mitjans, M., Arias, B., & Arango, C. (2014). Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra. *Revista de Psiquiatría y Salud Mental*, 7(4), 166-178.
<https://doi.org/10.1016/j.rpsm.2014.05.004>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Abstract (English version)

Aim: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-individual genetic differences produce varying degrees of vulnerability to the different SGA-induced side effects. The Second-generation antipsychotic Long-term treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental and genetic factors that explain inter-individual differences in weight gain and metabolic changes in drug-naïve patients after six months of treatment with SGAs.

Materials and methods: The SLiM study is a multicenter, observational, six-month pharmacogenetic study where a cohort of 307 drug-naïve paediatric and adult patients (age range 8.8 - 90.1 years) and a cohort of 150 age- and sex- matched healthy controls (7.8 – 73.2 years) were recruited.

Results: This paper describes the rationale, objectives and design of the study and provides a description of the sample at baseline.

Conclusions: Results from the SLiM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment.

Keywords: Antipsychotic Agents; Weight Gain; Metabolic Syndrome; Pharmacogenetics; Drug-Related Side Effects and Adverse Reactions.

Abstract (castellano)

Objetivo: El aumento de peso es un efecto secundario frecuente e importante producido por los antipsicóticos de segunda generación (ASGs). Además, estos fármacos pueden inducir otros efectos secundarios asociados a un aumento de la morbilidad y mortalidad cardiovascular, tales como la resistencia a insulina, la diabetes o el síndrome metabólico. Estudios preliminares sugieren que diferencias genéticas interindividuales producen distintos grados de vulnerabilidad a los efectos secundarios inducidos por los ASGs. El estudio SLIM (por sus siglas en inglés, *Second-generation antipsychotic Long-term treatment Metabolic side effects*) tiene como objetivo identificar en pacientes *naïve* a ASGs, factores clínicos, genéticos y ambientales que expliquen las diferencias interindividuales en relación con el aumento de peso y los cambios metabólicos generados tras seis meses de tratamiento con estos fármacos.

Material y métodos: El estudio SLIM es un estudio farmacogenético multicéntrico, observacional, prospectivo, de seis meses de duración, en el que se ha reclutado una cohorte de 307 pacientes pediátricos y adultos (rango de edad 8,8 a 90,1 años) *naïve* a ASGs y una cohorte de 150 controles sanos (rango de edad 7,8 a 73,2 años) emparejados por edad y sexo.

Resultados: En este artículo se presentan la justificación, los objetivos y el diseño del estudio y se ofrece una descripción de la muestra al inicio del estudio.

Conclusiones: Los resultados del estudio SLIM permitirán una mejor comprensión de los factores clínicos, ambientales y genéticos implicados en el aumento de peso y los trastornos metabólicos asociados al tratamiento con ASGs.

Palabras clave: Agentes antipsicóticos; Aumento de peso; Síndrome metabólico; Farmacogenética; Efectos secundarios y reacciones adversas a medicamentos.

Introduction

The prescription of second-generation antipsychotics (SGAs) has dramatically increased in recent years in pediatric and adult population, both for psychotic and non-psychotic disorders^{1,2}. Despite a better extra-pyramidal side effect profile than classic antipsychotics, overall, SGAs are associated with a higher prevalence of metabolic and endocrine disturbances, such as weight gain, dyslipidaemia or glycemic abnormalities^{3,4}. These disturbances lead to a higher risk of cardiovascular disease and to an increased morbidity and mortality in these patients, as compared with the general population^{5,6}. Furthermore, metabolic adverse events have been associated with non-adherence to treatment and poor quality of life⁷⁻⁹.

Currently, optimization of antipsychotic treatment is limited by the high variability of response to treatment and tolerability among individuals. This variability is related to clinical heterogeneity, genetic, environmental and social factors¹⁰ and has hindered the use of pharmacogenomic (PGx) testing or genotype-based prescription in clinical practice^{11,12}. However, PGx-related techniques could help the identification of patients at higher risk of developing SGA-induced side effects through the identification of PGx biomarkers^{13,14}.

The purpose of the Second-generation antipsychotic Long-term treatment Metabolic side effect study (SLiM study), a multicenter, longitudinal, 6-month follow-up PGx study, was to identify clinical, environmental and genetic predictive factors of weight gain and metabolic changes in a Spanish sample of drug-naïve paediatric and adult patients treated with SGAs, and a cohort of age- and sex- matched healthy controls. The specific goals of the study were: 1) to assess the prevalence of anthropometric and metabolic changes after six months of treatment with SGAs, 2)

to assess the association between weight gain / metabolic changes and clinical improvement / non-adherence to treatment / quality of life, 3) to analyze polymorphisms in candidate genes related to appetite control, central nervous system homeostatic regulation, and obesity, 4) to assess the association between the analyzed genotypes, weight gain and metabolic changes, and 5) to identify risk genotypes that explain inter-individual differences in SGA-induced weight gain and metabolic disturbances.

This paper describes the rationale, objectives and design of the SLiM study and provides a description of the sample at baseline.

Subjects and methods

Recruitment procedure

From January 2007 to December 2010, seven sites from the Spanish Psychiatric Research Network (CIBERSAM) (see www.cibersam.es) recruited a sample of 307 paediatric and adult patients consecutively attended in their clinical facilities and prescribed an SGA for the first time or with a prior lifetime exposure to antipsychotics of no more than 10 days. A cohort of 150 age- and sex- matched healthy control subjects was also recruited. Table 1 displays the number of patients and controls included in the study per participating site.

[Place Table 1 about here]

Patients were recruited from emergency rooms, inpatient units, and outpatient clinics. The inclusion criteria for patients were: (i) presence of a psychiatric disorder according to DSM-IV criteria¹⁵, (ii) capacity to give written informed consent (from participants and from their parents or legal guardians when needed), and (iii) being

drug-naïve patients (first prescription of an SGA, or, if previously treated, a total lifetime exposure to antipsychotics of no more than 10 days). The initial design of the SLiM study only considered those patients who were firstly prescribed risperidone, olanzapine and quetiapine. Later on, this inclusion criterion was broadened and prescription with other SGAs was also allowed. Concomitant treatment with stimulants, mood stabilisers, antidepressants, anticholinergic agents, and benzodiazepines/hypnotics was also allowed. Presence of a severe medical condition was the unique exclusion criterion for patients.

Healthy controls were recruited among patients' friends, colleagues and neighbors. Inclusion criteria for controls were (i) absence of any psychiatric diagnosis according to DSM-IV criteria¹⁵ and (ii) capacity to give written informed consent (from participants and from their legal guardians/representatives when needed). Exclusion criteria for controls were (i) presence of a severe medical condition, and (ii) current or past treatment with any antipsychotic drug. The controls were compensated for their time with a 25 € gift card at each visit.

Figure 1 shows a flowchart of the recruitment procedure. Out of the 415 patients and 153 controls initially identified, 307 patients and 150 controls met the inclusion criteria and completed the baseline assessment. Out of these, 163 patients and 133 controls completed the 6 month follow-up period. Reasons for drop-out were: refusal to continue, loss to follow-up, SGA discontinuation (only for patients), death and other reasons (reason was specified). Shift to or addition of a new SGA during the follow-up was not considered a reason for drop-out.

[Place Figure 1 about here]

Design

The SLiM study is a prospective, observational, six-month study, in which four assessment visits (at baseline, 6 weeks, 3 months and 6 months) were performed for patients and controls. At baseline, a complete evaluation (which included recording of demographic, diagnostic and clinical data, clinical scales, recording of psychopharmacological treatment and side effects, an anthropometric and cardiovascular study, and collection of fasting blood and urine samples) was performed in the setting where subjects had been recruited. Later on, subjects were contacted by telephone and the same assessments were repeated at 6 weeks, 3 months and 6 months in a psychiatric outpatient setting. A review of the diagnosis and of the ongoing pharmacologic treatment, and an assessment of change in global psychopathology were also added. Taking the respective anthropometric, cardiovascular and blood test data, and based on established criteria, presence of insulin resistance¹⁶ and presence of metabolic syndrome¹⁷⁻¹⁹ were determined at each visit. For each participant, after the last completed visit, a completion sheet was filled out. Date of last visit and reasons for drop-out (where appropriate) were registered. Table 2 summarizes the assessments and their timing throughout the study.

[Place Table 2 about here]

Demographic and clinical assessment

An “ad hoc” protocol for recording of demographic data was designed. Age, sex, ethnicity, civil status, educational and occupational level of the participant (or his/her parent or legal guardian if under 18 years of age) were recorded.

Diagnosis was made by experienced psychiatrists according to DSM-IV criteria¹⁵, by means of a clinical interview and a review of medical records of the participant. Also, information on personal medical history (including type 1 and 2 diabetes mellitus), family history of type 1 and 2 diabetes mellitus and/or hyperlipidemia, personal and family history of psychiatric disorder, number and duration of hospitalizations (for patients), pregnancy, and substance misuse was recorded. Data on somatic and psychopharmacological treatment was also recorded, including dosage, dosage changes, and start and discontinuation dates of any previous and/or current treatment. Antipsychotic doses were derived to chlorpromazine equivalents and current and cumulative doses at each visit were calculated^{20, 21}.

The anthropometric study was performed by trained nurses. Weight (in kilograms) and height (in meters) were measured at each visit with the same scale: SECA GMBH & Co., Model 797, in Hospital General Universitario Gregorio Marañón (HGUGM) and Oviedo Mental Health Service (OMHS); Año Sayol, Model Atlantida, in Hospital de la Santa Creu i Sant Pau (HSCSP) and Hospital Universitario Ramón y Cajal (HURC); Soehnle 7831 Digital Scale in Hospital Universitario Santiago Apóstol (HUSA); Body Composition Analyzer BF-350, Tanita Corporation, in Hospital Universitario 12 de Octubre (HU12O); OMRON BF-500 in Hospital Clínico Universitario Valencia (HCUV). From this data, body mass index (BMI) was

calculated as follows: weight (kilograms) / height (square meters). Because BMI varies according to age and sex, the BMI value for these variables was adjusted using a conversion to a z-score. For children and adolescents, BMI was adjusted for age and sex using Spanish normative charts²². For adults, raw scores were transformed to z -scores based on the BMI of the sex-matched control group at each visit. Abdominal circumference was measured using a flexible tape measure located above the upper edge of the iliac crests. Total body fat mass was measured at each visit with the same bioelectrical impedance scale: OMRON BF-500 in HGUGM, OMHS, HUSA, HURC and HCUV; OMRON BF-511 in HSCSP; Tanita BF-350 in HU12O). At each visit, participants were asked whether they were on diet and whether they had experienced changes in appetite and/or in food intake. Information on the amount of physical activity (i.e. hours per week of physical activity during last week) was also recorded.

A Cardioline Delta 1 Plus Digital ECG, Versione Base (Renco, Italy) in HGUGM, Cardioline AR600ADV ECG (Cavareno, Italy) in OMHS, Philips M1772A ECG (Andover, MA, USA) in HSCSP, Philips Page Writer Trim I ECG (Eindhoven, The Netherlands) in HUSA, Philips Page Writer TC30 ECG (Andover, MA, USA) in HURC, Cardiovit AT-2 ECG, Schiller AG (Baar, Switzerland) in HU12O and Nihon Kohden Cardio FAX V Ecaps 12 (Rosbach, Germany) in HCUV were used for the ECG assessment. Recording of sitting blood pressure (BP) and heart rate was also performed. For children, raw BP values were derived to percentiles according to the International Task Force for BP²³.

The Clinical Global Impression- Severity (CGI-S) scale²⁴ and the Clinical Global Impression– Improvement (CGI-I) scale²⁴ were completed by experienced

psychiatrists. These scales assess severity and improvement, respectively, of global symptomatology on a scale of 1 to 7. They are particularly helpful in longitudinal studies as they provide an ordinal repeated measure of global clinical status.

The Impact of Weight on Quality of Life (IWQOL-Lite) scale²⁵ and the Scale of the *Udvalg for Kiniske Undersogelser* (UKU) scale²⁶ were also administered throughout the study by trained psychiatrists. The IWQOL-Lite scale is a 31-item self-report scale of obesity-specific quality of life which consists of a total score and scores on five subscales (i.e. physical function, self-esteem, sexual life, public distress, and work). The UKU scale is a comprehensive rating scale including a total of 54 items (divided in four categories) scored 0 to 3, designed to assess general side effects of psychotropic drugs.

Biochemical determinations

Venous blood samples were collected by nursery personnel in 7 polypropylene EDTA-containing and serum tubes in the morning (between 8:00 and 10:00) after fasting overnight and stored initially at 4 °C. One of the fresh blood samples was sent to the Biochemistry Department of each participating site, where biochemical determinations were performed. Determinations included lipid profile, glucose, glycated hemoglobin A1 (HbA1c), and insulin levels. In all the participating sites, blood glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and triglycerides (TG) were determined by enzymatic procedures with an Automatic Chemical Analyzer. HbA1c was analyzed by high-performance liquid chromatography (HPLC). Insulin was measured by immunoassay with chemiluminescence detection. The Biochemistry Department of

each participating site recorded the biochemical data by means of the pre-established criteria for normality (minimum and maximum) for each parameter. The reference values at each site were recorded and individual values were corrected and homogenized in the common database.

For both patients and controls, another blood tube was centrifuged (2000 g x 10 min, room temperature) after 1 hour of storage. The resultant serum samples were carefully collected in serum tubes and stored at $\leq -20^{\circ}\text{C}$ until they were sent to the Biochemistry laboratory of the coordinating site (HGUGM), where adiponectin and leptin levels were determined (in duplicate) by Enzyme-Linked Immune Sorbent (ELISA) assay (Human Leptin ELISA [ref: RD191001100], Human Adiponectin ELISA [ref: RD195023100]; all Biovendor Laboratory Medicine Inc., Brno; Czech Republic). All these determinations were performed by a trained and experienced biochemist.

Serum SGA determinations

For each patient and at each visit, one of the stored serum samples was also sent to the Biochemistry laboratory of the coordinating site (HGUGM), where HPLC was performed by a trained and experienced biochemist using a Waters 2695 series HPLC system (Alliance HPLC system, Waters Corp. Milford, MA, USA). The analytes were separated on an Agilent Eclipse XDB C-18 column (150 x 4.6 mm i.d., 5 μm) with a 4.6 x 12.5 mm Eclipse XDB C-18 guard column, following the protocol described by Zhang et al²⁷. This semi-quantitative technique provided an indirect measure of patient's adherence to SGAs at each visit (by means of a 'positive' or 'negative' HPLC test).

Genotype analyses

For each participant, one of the collected blood samples was stored at $\leq -20^{\circ}\text{C}$ until it was sent to the College of Biology of the University of Barcelona. Here, an experienced and trained geneticist performed DNA processing (i.e. coding, storage and extraction, using a commercial extraction kit) and DNA genotyping. Candidate genes of the SLiM PGx study and their selected SNPs and MAFs are summarized in Supplementary Table 1. Candidate genes related to SGA mechanism of action, appetite control, homeostatic regulation and weight gain or related phenotypes (e.g., obesity) were selected according to previous association and genome wide association studies (GWAS) ²⁸⁻³⁵. Single Nucleotide Polymorphisms (SNPs) of these candidate genes were selected according to previous literature and the SYSNPS program (www.sysnps.org). SNPs were chosen from the SYSNPS program only if they were TagSNPs of the candidate gene and presented a Minor Allele Frequency (MAF) > 0.2 . This MAF criterion was used to increase the statistical power.

Genotyping was blind to group membership (patient vs. control) and SGA treatment. The 5-HTTLPR polymorphism (*SLC6A4* gene) was genotyped following a standard protocol³⁶. The rs6265 (*BDNF* gene) and rs1049353 (*CNR1* gene) were genotyped using Taqman 5'-exonuclease assay. All other SNPs were genotyped by competitive quantitative PCR using allele specific probes with FRET signal detection. A randomly selected subsample of individuals was re-genotyped in order to confirm the pattern of reproducibility.

[Place Table 3 about here]

Urine sampling

At each visit and for each participant, urine samples were collected and a routine urinalysis, pregnancies test (where appropriate) and urine drug tests were performed. Amphetamines, cannabis, cocaine, opiates, benzodiazepines and barbiturates were determined by immunoassay in HGUGM, HSCSP, HU12O, HUSA, and HURC; by endpoint spectrophotometry with monochromatic light in OMHS; and by thin-layer chromatography in HCUV.

Metabolic and cardiovascular risk assessment

Given the respective anthropometric and cardiovascular data, presence of metabolic syndrome was established for each patient at each visit. For adult participants, metabolic syndrome was defined following the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement¹⁹. For paediatric participants, metabolic syndrome was defined following an adaptation from the criteria by Cook et al., 2003¹⁷, and Correll and Carlson, 2006¹⁸. These criteria include a clustering of the most relevant risk factors for cardiovascular disease: abdominal obesity raised fasting plasma glucose and/or diabetes, abnormal lipid profile and high blood pressure (see Table 3).

Both for pediatric and adult participants, insulin resistance was estimated by means of the homeostasis model assessment- insulin resistance (HOMA-IR) index¹⁶,

which is easily calculated from a single measurement of fasting insulin and glucose (see Table 3).

[Table 3 about here]

Data processing and analysis

In order to integrate all the available information, and to facilitate data management and exploitation, a common database was created. Data entry, database design and management were centralized at the coordinating site.

For the description of the sample at baseline, continuous variables were expressed as means, standard deviations (SD) and ranges, and categorical variables were expressed as frequencies and percentages. Group differences were tested for baseline demographic and clinical data. The comparison groups were patients (whole sample) vs. controls (whole sample), paediatric vs. adult patients, and paediatric vs. adult controls. Chi-square or Fisher exact tests were used for discrete categorical variables. Since all the quantitative variables included in the analysis (age, days of previous SGA exposure, current and cumulative doses of SGA at baseline) showed non-normal distributions, non-parametric tests (Mann-Whitney U) were used. Statistical analyses were carried out with the SPSS 18.0³⁷ and differences of $p < 0.05$ were considered significant. All tests were two-tailed.

Results

Sample description at baseline

The demographic and clinical characteristics at baseline of the 307 (71 paediatric and 236 adult) patients and 150 (18 paediatric and 132 adult) healthy controls who were included in the study are shown in Table 4. Data on SGA and concomitant treatments, both in the whole sample and within each age group, are also shown in Table 4.

[Table 4 about here]

A significantly higher proportion of patients (47%) than healthy controls (11%) dropped out of the study during the follow-up. The main reasons for drop-out are shown in Figure 1 and Table 4.

Discussion

The SLiM study is the first 6-month prospective, observational, multicenter, pharmacogenetic (PGx) study including a large cohort of SGA drug-naïve patients across a large age span (8 to 90 years) and with a variety of diagnoses, and a cohort of healthy controls matched by age, sex and ethnicity. In our sample, the group of paediatric patients had a significantly higher proportion of males, a higher proportion of subjects diagnosed with a bipolar disorder and a higher proportion of severe patients (defined as having a CGI-S score ≥ 6) than the group of adult patients. Irrespective of age, almost 40% of patients were completely naïve to SGAs at

baseline. Risperidone was the most commonly prescribed SGA across the entire age span. Paediatric patients had higher prescription rates of risperidone, anticholinergic agents and stimulants at baseline than their adult counterparts. Conversely, olanzapine and antidepressants were more commonly prescribed in adults. Although not statistically significant, mean daily doses of prescribed SGAs were slightly lower in the paediatric than in the adult group.

SGAs other than risperidone, olanzapine and quetiapine were scarcely prescribed in our sample. This may be partly due to the study design. Initially, only those patients who were firstly prescribed with these three SGA drugs were included; further on, the inclusion criteria were broadened and prescription of any SGA was allowed. This may have biased the results in terms of prescription rates in both age groups. Nonetheless, our results were congruent with previous observational studies in similar settings, in which these were the most prescribed SGAs, both in paediatric^{38,39} and adult samples⁴⁰. Except for a patient that had been prescribed risperidone for aggression in the context of a conduct disorder and a low intelligence quotient, the rest of paediatric patients enrolled in the SLiM study were taking SGA drugs for off-label uses. Nonetheless, the fact that olanzapine was poorly prescribed in the paediatric group, points towards the increasing awareness of child and adolescent psychiatrists around the metabolic profile of this drug⁴¹. Regarding concomitant treatments, even though antidepressants are increasingly co-prescribed with antipsychotics in children and adolescents^{42,43}, co-prescription rates seem to be higher in adult population^{40,44}.

The SLiM study has a number of limitations that are inherent in its naturalistic design. Prescribed SGA treatment was not controlled and doses were chosen by the

treating psychiatrists, based on clinical criteria. Also, the sample was heterogeneous in terms of setting provenance, diagnoses, use of concomitant medications or presence of alcohol and substance misuse. This will be taken into account when carrying out further analyses of the clinical, environmental, and genetic factors that might be associated with weight gain and metabolic disturbances. The main difficulties that we encountered were the recruitment of drug-naïve patients and the control group matching strategy. That said, a relatively large cohort of drug-naïve patients and healthy controls was recruited and followed-up during 6 months. During the follow-up, one of the main difficulties that we encountered was the large drop-out rate (around 50% of patients and 11% healthy controls dropped out of the study). The main reason for drop-out both in adult and paediatric patients was the loss to follow-up (19.9% and 32.4%, respectively), while refusal to continue was more frequent in adults than in young people (8.5% vs. 1.4%, respectively). Discontinuation of the prescribed SGA was a reason for drop-out in around 14% of patients (both in adult and paediatric subgroups). Nonetheless, discontinuation rates may have been higher, since discontinuation may apply to some of the patients who were lost to follow-up or refused to continue participation. Furthermore, the controls were compensated with a gift card for their participation in the SLiM study. This may have led to a 'volunteer bias' (i.e. the bias that comes from the fact that a particular sample can contain only those participants who are actually willing to participate in the study or experiment⁴⁵). Nonetheless, the authors tried to control for this by means of a careful control group matching strategy. Another relevant limitation is that serum SGA determinations at each visit only provide an indirect measure of treatment adherence. Nonetheless, these determinations were centralized at one

site, where a trained and experienced biochemist performed the analyses following a standardized protocol.

The main strengths of this study include the prospective design of the study, with a 6-month follow-up, the homogeneity of the patient and control sample, the large age span of the recruited sample and the relatively large sample size considering the above mentioned characteristics of the sample. This strategy will increase the power of the PGx study with few confounding factors and carry-over effects.

Results from the SLiM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment. Additionally, we will be able to explore the effect of age in such changes and the impact of weight gain in clinical outcome and quality of life of drug-naïve patients treated with SGAs. Finally, the study will enable the identification of potential PGx biomarkers as predictors for SGA tolerability. In the near future, this could potentially assist the individualization of antipsychotic treatment and facilitate the development of new therapeutic tools with better safety and tolerability profiles.

Ethical disclosures

All the subjects included in the study and/or their legal representatives received the information about the study and provided written informed consent for participation. Privacy and confidentiality of data were warranted throughout the study. The study

complied with Spanish regulatory legislation, received institutional approval in all the participating sites, and was conducted according to the provisions of the World Medical Association Declaration of Helsinki.

Funding sources

This study was funded by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness (PI 06/1165, PI 07/0815, PI 07/0163, and PI 07/0452), Beca Intramural CIBERSAM 2008 and Fundación Mutua Madrileña 2009.

Acknowledgements

Supported by the Spanish Ministry of Economy and Competitiveness. Instituto de Salud Carlos III, CIBERSAM. Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds, Fundación Alicia Koplowitz, Fundación Mutua Madrileña and The Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya (2009 SGR 827).

Conflict of interest

LP-C and CMD-C have received a grant 'Río Hortega' from Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness and from Fundación Alicia Koplowitz.

JB has been a consultant to or has received honoraria or grants from Adamed, AstraZeneca, Bristol-Myers Squibb, CIBERSAM, D&A Pharma, Elan, European Commission –FP6 and FP7-, Forest, Instituto de Salud Carlos III, Janssen Cilag, Lilly, Lundbeck, Ministerio de Sanidad, Plan Nacional sobre Drogas, Otsuka, Pfizer, Roche, Servier and Shire.

IC has received honoraria or grants from Lilly, Janssen and Otsuka.

RRJ has been a consultant to or has received honoraria or grants from CIBERSAM, Instituto de Salud Carlos III, Lundbeck, Otsuka, Pfizer.

JS has been a consultant or has received research grants from Ministerio de Economía y Competitividad Conselleria de Sanidad, ISCIII, TV3, Lilly, Janssen, Otsuka, Roche, Pfizer, and Astra Zeneca.

AG-L has received research grants and served as consultant advisor or speaker for AstraZeneca, Eli Lilly, Boehringer Ingelheim, Lundbeck, Pfizer and Servier.

DF has been a consultant and/or advisor to or has received honoraria from AstraZeneca, Bristol-Myers-Squibb, Janssen, Lundbeck, Otsuka and Pfizer.

CA has been a consultant to or has received honoraria or grants from Abbot, AMGEN, AstraZeneca, Bristol-Myers Squibb, Caja Navarra, CIBERSAM, Fundación Alicia Koplowitz, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Merck, Ministerio de Ciencia e Innovación, Ministerio de Sanidad, Ministerio de Economía y Competitividad, Mutua Madrileña, Otsuka, Pfizer, Roche, Servier, Shire, Takeda and Schering Plough.

PAS, EG, MF, CT-C, MA-B, MM and BA have no conflict of interest to declare.

References

1. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. *Arch Gen Psychiatry*. 2012;69(12):1247-56.
2. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. *Br J Psychiatry*. 2012;200(5):393-8.
3. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. *Eur Neuropsychopharmacol*. 2011;21(8):621-45.
4. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013;382(9896):951-62.
5. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. *Schizophr Res*. 2007;90(1-3):162-73.
6. De Hert M, Dekker JM, Wood D, Kahl KG, Möller HJ. Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave. *Rev Psiquiatr Salud Ment*. 2009;2(1):49-59.
7. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. *Schizophr Res*. 2004;66(1):51-7.

8. Vancampfort D, Probst M, Scheewe T, Maurissen K, Sweers K, Knapen J, et al. Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia. *Schizophr Res.* 2011;129(2-3):122-7.
9. Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. *BMC Psychiatry.* 2012;12:20.
10. Lohoff FW, Ferraro TN. Pharmacogenetic considerations in the treatment of psychiatric disorders. *Expert Opin Pharmacother.* 2010;11(3):423-39.
11. Arranz MJ, Gutierrez B. Pharmacogenetics in psychiatry: the need to prove its benefits. *Rev Psiquiatr Salud Ment.* 2011;4(3):117-8.
12. Lunshof JE, Gurwitz D. Pharmacogenomic testing: knowing more, doing better. *Clin Pharmacol Ther.* 2012;91(3):387-9.
13. Costa e Silva JA. Personalized medicine in psychiatry: new technologies and approaches. *Metabolism.* 2013;62 Suppl 1:S40-4.
14. Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. *Trends Pharmacol Sci.* 2011;32(2):72-81.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 1985;28(7):412-9.

17. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. *Arch Pediatr Adolesc Med*. 2003;157(8):821-7.
18. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. *J Am Acad Child Adolesc Psychiatry*. 2006;45(7):771-91.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. *Cardiol Rev*. 2005;13(6):322-7.
20. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. *Biol Psychiatry*. 2010;67(3):255-62.
21. Rijcken CA, Monster TB, Brouwers JR, de Jong-van den Berg LT. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? *J Clin Psychopharmacol*. 2003;23(6):657-9.
22. Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizárraga A, et al. Curvas y tablas de crecimiento: estudios longitudinal y transversal. Bilbao: Fundación Faustino Orbegoza Eizaguirre; 2004.
23. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*. 2004;114(2 Suppl 4th Report):555-76.

24. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
25. Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample. *Qual Life Res.* 2002;11(2):157-71.
26. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. *Acta Psychiatr Scand Suppl.* 1987;334:1-100.
27. Zhang G, Terry AV, Jr., Bartlett MG. Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2007;856(1-2):20-8.
28. Balt SL, Galloway GP, Baggott MJ, Schwartz Z, Mendelson J. Mechanisms and genetics of antipsychotic-associated weight gain. *Clin Pharmacol Ther.* 2011;90(1):179-83.
29. Lencz T, Malhotra AK. Pharmacogenetics of antipsychotic-induced side effects. *Dialogues Clin Neurosci.* 2009;11(4):405-15.
30. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. *Mol Psychiatry.* 2012;17(3):242-66.
31. Meyre D, Delplanque J, Chevre JC, Lecoecur C, Lobbens S, Gallina S, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. *Nat Genet.* 2009;41(2):157-9.

32. Risselada AJ, Mulder H, Heerdink ER, Egberts TC. Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. *Pharmacogenomics*. 2011;12(8):1213-27.
33. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet*. 2010;42(11):937-48.
34. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadóttir A, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet*. 2009;41(1):18-24.
35. Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, Heid IM, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat Genet*. 2009;41(1):25-34.
36. Cervilla JA, Molina E, Rivera M, Torres-Gonzalez F, Bellon JA, Moreno B, et al. The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-Gene cohort. *Mol Psychiatry*. 2007;12(8):748-55.
37. SPSS Inc. PASW Statistics for Windows. 18.0 ed. Chicago: SPSS Inc.; 2009.
38. Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, Gonzalez-Pinto A, Graell M, et al. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. *J Child Adolesc Psychopharmacol*. 2008;18(4):327-36.
39. Merchan-Naranjo J, Tapia C, Bailon C, Moreno C, Baeza I, Calvo-Escalona R, et al. Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results. *Rev Psiquiatr Salud Ment*. 2012;5(4):217-28.

40. Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. *Acta Psychiatr Scand Suppl.* 2003(416):7-15.
41. Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. *Eur Child Adolesc Psychiatry.* 2009;18(7):418-28.
42. Diaz-Caneja CM, Espliego A, Parellada M, Arango C, Moreno C. Polypharmacy with antidepressants in children and adolescents. *Int J Neuropsychopharmacol.* 2012:1-20.
43. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. *J Am Acad Child Adolesc Psychiatry.* 2010;49(10):1001-10.
44. Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. *J Clin Psychiatry.* 2008;69(2):240-5.
45. Heiman GW. *Research Methods in Psychology.* 3rd ed. Boston & New York: Houghton Mifflin Company; 2002.

Table 1 Included patients and controls per participating site

	Patients		Controls	
	N	%	N	%
Hospital Universitario Gregorio Marañón (HGUGM), Madrid*	120	39.1	53	35.3
Oviedo Mental Health Services (OMHS), Oviedo	87	28.3	20	13.3
Hospital de la Santa Creu i Sant Pau (HSCSP), Barcelona	45	14.6	19	12.7
Hospital Universitario Santiago Apóstol (HUSA), Vitoria	19	6.2	21	14.0
Hospital Universitario 12 de Octubre (HU12O), Madrid	18	5.9	25	16.7
Hospital Universitario Ramón y Cajal (HURC), Madrid	10	3.3	8	5.3
Hospital Clínico Universitario de Valencia (HCUV), Valencia	8	2.6	4	2.7
Total	307	100	150	100

*Coordinating site

Table 2 Assessments and timing

	Baseline	6 th week	3 rd month	6 th month
Demographic and clinical assessments				
Demographic data	X			
Diagnostic (DSM-IV) and clinical interview	X	X	X	X
Medication	X	X	X	X
Family history of diabetes mellitus type 1 and 2	X			
Family history of hyperlipidemia	X			
Anthropometric study	X	X	X	X
Cardiovascular study	X	X	X	X
Physical activity	X	X	X	X
Diet, appetite and intake	X	X	X	X
CGI-S scale	X	X	X	X
CGI-I scale		X	X	X
IWQOL-Lite scale	X	X	X	X
UKU tolerability scale	X	X	X	X
Blood sampling				
Biochemical/metabolic testing	X	X	X	X
Serum levels of SGA (HPLC)	X	X	X	X
Genetic testing	X			
Urine sampling				
Routine urinalysis	X	X	X	X
Pregnancy test (where appropriate)	X	X	X	X
Urine drug testing	X	X	X	X
Metabolic and cardiovascular risk assessments				
Metabolic syndrome	X	X	X	X
HOMA-IR index	X	X	X	X
Completion sheet				
Date of last visit	Last completed visit			
Reasons for drop-out (where appropriate)	Last completed visit			

Abbreviations: CGI-I: Clinical Global Impression- Improvement; DSM-IV: Diagnostic and statistical manual of mental disorders, 4th edition; HOMA-IR: Homeostasis model assessment-estimated insulin resistance; HPLC: High-

performance liquid chromatography; IWQOL-Lite: Impact of Weight on Quality of Life; SGA: second-generation antipsychotic; UKU: *Udvalg for Kliniske Undersøgelser*.

Table 3 Criteria for presence of metabolic syndrome and insulin resistance in paediatric and adult populations.

	Adult patients	Paediatric patients
Metabolic syndrome	^a <p>≥3 of the following:</p> <ul style="list-style-type: none"> - Waist circumference ≥ 102 cm in males or ≥ 88 cm in females - Glucose ≥100 mg/dl - Triglycerides ≥150 mg/dl - HDL cholesterol <40 in males or <50 in females. - Blood pressure ≥ 130/85 mmHg 	^{b,c} <p>≥3 of the following:</p> <ul style="list-style-type: none"> - BMI ≥ 95th percentile or waist circumference ≥ 90th percentile - Glucose ≥ 100 mg/dl - Triglycerides ≥110 mg/dl - HDL cholesterol <40 mg/dl - Blood pressure ≥ 90th percentile
HOMA-IR ^d	Fasting glucose (mg/dl) *Insulin (μU/ml)/405	

^a Grundy et al., 2005¹⁹; ^b Cook et al., 2003¹⁷; ^c Correl and Carlson, 2006¹⁸; ^d Matthews et al., 1985¹⁶

Abbreviations: BMI: body mass index. HDL: high density lipoprotein, HOMA-IR: homeostasis model assessment-insulin resistance.

Table 4 Demographic and clinical characteristics at baseline of paediatric and adult patients and controls

	Patients				Controls				
	Total (N=307)	Paediatric (N=71)	Adult (N=236)	Paed vs. adults*	Total (N=150)	Paediatric (N=18)	Adult (N=132)	Paed vs. adults*	Patients vs. Controls*
Age (years), mean (SD), [range]	37.5 (19.9)	15.9 (1.6)	44.0 (18.4)	0.001	34.1 (13.7)	15.2 (2.8)	36.7 (12.5)	0.001	0.556
	[8.8 – 90.1]	[8.8 - 17.9]	[18.0 – 90.1]		[7.8 - 73.2]	[7.8 – 17.8]	[18.4 – 73.2]		
Male sex, N (%)	169 (55.0)	49 (69.0)	120 (50.8)	0.007	71 (47.3)	11 (61.1)	60 (45.5)	0.212	0.121
Ethnicity, N (%) ^a									
Caucasian	260 (85.5)	53 (75.7)	207 (88.5)	0.052	137 (91.9)	13 (72.2)	124 (94.7)	0.001	0.172
Hispanic	25 (8.2)	8 (11.4)	17 (7.3)		10 (6.7)	3 (16.7)	7 (5.3)		
Other	19 (6.2)	9 (12.9)	10 (4.3)		2 (1.3)	2 (11.1)	0 (0)		
Diagnosis (DSM-IV criteria), N (%)^b									
Schizophrenia spectrum disorders	42 (14.0)	9 (12.9)	33 (14.3)	0.779	---	---	---	---	---
Bipolar disorder	28 (9.3)	14 (20.0)	14 (6.1)	0.001					
Other psychotic disorders	108 (36.0)	26 (37.1)	82 (35.7)	0.772					
Depressive disorders	35 (11.7)	1 (1.4)	34 (14.8)	0.003					
OCD	1 (0.3)	0 (0)	1 (0.4)	0.999					
Other anxiety disorders	9 (3.0)	0 (0)	9 (3.9)	0.124					

Substance disorders	9 (3.0)	0 (0)	9 (3.9)	0.124
Adjustment disorders	14 (4.7)	3 (4.3)	11 (4.8)	0.999
Dissociative disorders	2 (0.7)	1 (1.4)	1 (0.4)	0.410
Somatoform disorders	3 (1.0)	2 (2.9)	1 (0.4)	0.135
Eating disorders	1 (0.3)	0 (0)	1 (0.4)	0.999
Sleep disorders	3 (1.0)	0 (0)	3 (1.3)	0.999
Personality disorders	16 (5.3)	5 (7.1)	11 (4.8)	0.541
Mental retardation	3 (1.0)	0 (0)	3 (1.3)	0.999
Autism spectrum disorders	2 (0.7)	1 (1.4)	1 (0.4)	0.410
ADHD	5 (1.7)	5 (7.1)	0 (0)	0.001
Conduct disorder/ ODD	2 (0.7)	2 (2.9)	0 (0)	0.053
Other infancy/ childhood / adolescence	1 (0.3)	1 (1.4)	0 (0)	0.231
Delirium	10 (3.3)	0 (0)	10 (4.3)	0.124
Dementia	6 (2.0)	0 (0)	6 (2.6)	0.342
CGI- severity, N (%) ^c				
Mild (1-3)	26 (9.9)	11 (15.9)	15 (7.7)	0.001
Moderate (4-5)	201 (76.4)	36 (52.2)	165 (85.1)	
Severe (6-7)	36 (13.7)	22 (31.9)	14 (7.2)	
Treatment status at baseline, N (%) ^d				

-

Completely-naïve	121 (39.4)	27 (38.0)	94 (39.8)	0.785	---	---	---	---	---
Prior exposure to SGA ≤ 10 days	186 (60.6)	44 (62.0)	142 (60.2)						
Before baseline visit	184 (59.9)	43 (60.6)	141 (59.7)						
In the past	2 (0.7)	1 (1.4)	1 (0.5)						
Prescribed SGA at baseline, N (%) ^e									
Risperidone	126 (41.0)	51 (71.8)	75 (31.8)	0.001	---	---	---	---	---
Olanzapine	77 (25.1)	3 (4.2)	74 (31.4)	0.001					
Quetiapine	88 (28.7)	15 (21.1)	73 (30.9)	0.109					
Other ^f	16 (5.2)	2 (2.8)	14 (5.9)	0.378					
Previous SGA exposure (days), mean (SD), median, [range]	2.4 (2.7), 2.0 [0 – 10]	2.1 (2.4), 2.0 [0 – 10]	2.5 (2.8), 1.5 [0 – 10]	0.372	---	---	---	---	---
Current dose of SGA at baseline (mg), mean (SD), [range] ^g	145.7 (185.7) [0 – 1200]	123.5 (142.1) [0 – 530.3]	152.2 (196.5) [0 – 1200]	0.736	---	---	---	---	---
Cumulative dose of SGA at baseline (mg), mean (SD), [range] ^h	560.9 (859.7) [0 – 6105.3]	377.4 (545.8) [0 – 2727.3]	614.8 (926.1) [0 – 6105.3]	0.330	---	---	---	---	---
Concomitant treatment, N (%) ⁱ									
Antidepressants	78 (25.6)	5 (7.2)	73 (30.9)	0.001	---	---	---	---	---
Lithium	3 (1.0)	0 (0.0)	3 (1.3)	0.999					
Other mood stabilizers	25 (8.2)	3 (4.3)	22 (9.3)	0.185					
Stimulants	5 (1.6)	5 (7.0)	0 (0)	0.001					
Benzodiazepines	142 (46.4)	26 (37.1)	116 (49.2)	0.077					

Anticholinergic agents	12 (3.9)	8 (11.3)	4 (1.7)	0.001					
Drop-out before 6th month assessment, N (%) ^j	144 (46.9)	36 (50.7)	108 (45.8)	0.464	17 (11.3)	3 (16.7)	14 (10.6)	0.432	0.001
Refusal to continue	21 (6.8)	1 (1.4)	20 (8.5)	0.034	3 (2.0)	2 (11.1)	1 (0.8)	0.038	0.027
Loss to follow-up	70 (22.8)	23 (32.4)	47 (19.9)	0.034	14 (9.3)	1 (5.6)	13 (9.8)	0.999	0.001
SGA discontinuation	42 (13.7)	10 (14.1)	32 (13.6)	0.950	---	---	---	---	---
Death ^k	1 (0.3)	0 (0)	1 (0.4)	0.999	0 (0)	0 (0)	0 (0)	---	0.999
Other reasons	6 (2.0)	2 (2.8)	4 (1.6)	0.628	0 (0)	0 (0)	0 (0)	---	0.185
Unknown	4 (1.3)	0 (0)	4 (1.6)	0.577	0 (0)	0 (0)	0 (0)	---	0.308

In all cells, % refers to percentages (within columns) of participants for whom information was available. Abbreviations: CGI: clinical global impression; Paed: paediatric; SGA: second-generation antipsychotic.

* Statistically significant p-values in bold. For qualitative variables, Chi-square tests (χ^2) (Fisher exact test when needed). For quantitative variables, Mann-Whitney U tests.

^a Information available for 304 patients and 149 controls.

^b Information available for 300 patients. Diagnosis refers to the psychiatric condition for which the SGA was prescribed. Forty-five patients had a co-morbid Axis I or Axis II diagnosis (data available upon request). ADHD: Attention deficit and hyperactivity disorder. Depressive disorders: major depressive disorder, dysthymia, and depressive disorder not otherwise specified. OCD: Obsessive-compulsive disorder. ODD: Oppositional defiant disorder. Other anxiety disorders: generalized anxiety disorder, anxiety disorder not otherwise specified, and posttraumatic stress disorder. Other infancy / childhood / adolescence: other disorders of infancy, childhood, or adolescence. Other psychotic disorders: brief reactive psychosis, psychotic disorder not otherwise specified, major depressive disorder with psychotic symptoms, substance-induced psychosis, and delusional disorder. Schizophrenia spectrum disorders: schizophrenia, schizophreniform and schizoaffective disorder.

^c Information available for 263 patients.

^d Information available for 307 patients. Completely-naïve refers to those patients who were prescribed an SGA for the first time just at the time the baseline visit was performed. Prior exposure to SGA ≤ 10 days refers to those patients who had a prior lifetime exposure to antipsychotics of no more than 10 days, either because they had been prescribed an SGA right before the baseline visit or in the past.

^e Information available for 307 patients. Other SGAs: paliperidone (n=6 adult patients), aripiprazol (n=2 paediatric and 4 adult patients), amisulpride (n=2 adult patients), asenapine (n= 1 adult patient), combination of olanzapine + sulpride (n=1 adult patient).

^h In chlorpromazine equivalents: 100 mg chlorpromazine = about 1.5 mg risperidone / 5 mg olanzapine / 150 mg quetiapine.

ⁱ Information available for 305 patients.

^j Information available for 303 patients and 150 controls.

^k Death was caused by complications of a diagnosed dementia disorder.

Figure 1 Flowchart for study design

^a Death was caused by complications of a diagnosed dementia disorder.

Abbreviations: FGA: first-generation antipsychotic; SGA: second-generation antipsychotic.